Bolt Biotherapeutics Prices Upsized Initial Public Offering
About Admin Boltbio
This author has yet to write their bio.
Meanwhile lets just say that we are proud Admin Boltbio contributed a whooping 6 entries.
Bolt Biotherapeutics Expands Board of Directors with Appointment of Kathleen LaPorte
Bolt Biotherapeutics Presents Ongoing Clinical Trial Poster at San Antonio Breast Cancer Symposium 2020 Virtual Meeting
Data Published in Nature Cancer Highlight Preclinical Proof of Concept of Bolt Biotherapeutics’ Boltbody™ ISAC Platform
Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity Ackerman SE, et al., Nature Cancer (2020)
Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 as a single agent and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors Presented at: 2020 San Antonio Breast Cancer Symposium
You acknowledge that the personal information you provide to Bolt Biotherapeutics will be processed to respond to your request or inquiry. For more information, please review our Privacy Notice .